Journal Article

DZNE-2026-00216

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Accuracy of clinical diagnosis in neurodegenerative diseases - a study of 455 autopsy cases.

Vöglein, J. (First author)DZNE* ; Arzberger, T.DZNE* ; Ebner, I. ; Herms, J.DZNE* ; Roeber, S. ; Ruf, V. ; Danek, A.Extern* ; Giese, A. ; Höglinger, G. U.DZNE* ; Levin, J. (Last author)DZNE*

2026
Steinkopff [Darmstadt]

This record in other databases:    

Please use a persistent id in citations: doi:10.1007/s00415-026-13680-w

Abstract: Precision of clinical diagnosis in neurodegenerative diseases is critically important for clinical care and study recruitment. This study aimed to investigate the clinical accuracy using gold-standard neuropathological reference.Neuropathological diagnoses from the Neurobiobank München were correlated with real-world clinical diagnoses from hospitals in Germany. Accuracy metrics, including sensitivity, specificity, and area under the curve (AUC) of clinical diagnoses, were calculated.Among nine neuropathologically diagnosed neurodegenerative diseases (Alzheimer's disease, argyrophilic grain disease, corticobasal degeneration, frontotemporal lobar degeneration, Huntington's disease, Lewy body disease, motor neuron disease, multiple system atrophy, and progressive supranuclear palsy) with a total of 455 cases, clinical sensitivity varied widely (0-100%) whereas specificity was consistently high (89.5-100%). Accuracy was very good (AUC > 0.9) for Huntington's disease, motor neuron disease, and multiple system atrophy; good (AUC = 0.8-0.9) for Alzheimer's disease, dementia with Lewy bodies/Parkinson's disease, and progressive supranuclear palsy; moderate (AUC = 0.7-0.8) for frontotemporal dementia, limited (AUC = 0.51-0.7) in the n = 20 cases with corticobasal degeneration, and no discriminatory capacity (AUC = 0.5) in the n = 6 cases with argyrophilic grain disease.Clinical diagnostic accuracy of neurodegenerative diseases varies, with sensitivity as the main limiting factor. Improving diagnostic sensitivity will be essential for early and accurate patient identification, especially as disease-modifying therapies targeting causal proteinopathies become available. Achieving this will depend on the development and clinical implementation of reliable molecular biomarkers that indicate the causal proteinopathies of neurodegenerative diseases.

Keyword(s): Humans (MeSH) ; Neurodegenerative Diseases: diagnosis (MeSH) ; Neurodegenerative Diseases: pathology (MeSH) ; Male (MeSH) ; Female (MeSH) ; Aged (MeSH) ; Middle Aged (MeSH) ; Autopsy (MeSH) ; Aged, 80 and over (MeSH) ; Sensitivity and Specificity (MeSH) ; Adult (MeSH) ; Clinical diagnosis ; Clinical–neuropathological correlation ; Diagnostic accuracy ; Neurodegenerative diseases ; Neuropathology

---

Contributing Institute(s):

1. Clinical Research (Munich) (Clinical Research (Munich))
2. Clinical Neurodegeneration (AG Levin)
3. Translational Brain Research (AG Herms)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
2. 352 - Disease Mechanisms (POF4-352) (POF4-352)

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Springer ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---